Skip to content
Facebook page opens in new windowInstagram page opens in new windowYouTube page opens in new window
Search:
DONATE
ALD Connect
ALD ConnectALD Connect
  • About Us
    • Mission
    • Board of Directors
    • The Myelin Project
    • Our Partners
  • What is ALD?
    • ALD Centers and Experts
    • Newborn Screening/Asymptomatic
    • Adrenal Insufficiency
    • Cerebral ALD
    • Adrenomyeloneuropathy (AMN)
    • Symptomatic Women
  • Clinical Trials & Research
    • Clinical Trials
    • Emerging Investigators
    • The Grey Zone
    • Laboratories
    • Publications
  • Resources
    • Annual Meetings and Patient Learning Academies
    • EL-PFDD
    • Financial Assistance
    • Frequently Asked Questions
    • Peer Mentor Program
    • Webinars
  • Get Involved
    • 2023 ALD Connect Annual Meeting and Patient Learning Academy
    • Advocate
    • ALD Landscape Project
    • Community Calendar
    • Community Calls
    • Community Directory
  • News
  • Contact Us
  • About Us
    • Mission
    • Board of Directors
    • The Myelin Project
    • Our Partners
  • What is ALD?
    • ALD Centers and Experts
    • Newborn Screening/Asymptomatic
    • Adrenal Insufficiency
    • Cerebral ALD
    • Adrenomyeloneuropathy (AMN)
    • Symptomatic Women
  • Clinical Trials & Research
    • Clinical Trials
    • Emerging Investigators
    • The Grey Zone
    • Laboratories
    • Publications
  • Resources
    • Annual Meetings and Patient Learning Academies
    • EL-PFDD
    • Financial Assistance
    • Frequently Asked Questions
    • Peer Mentor Program
    • Webinars
  • Get Involved
    • 2023 ALD Connect Annual Meeting and Patient Learning Academy
    • Advocate
    • ALD Landscape Project
    • Community Calendar
    • Community Calls
    • Community Directory
  • News
  • Contact Us

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions

UncategorizedBy KellyMay 18, 2022

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions New funding will support ongoing clinical development of lead candidate, SBT101 for adrenomyeloneuropathy (AMN)…

© ALD Connect | Website Design & Website Development by Surf Your Name.
Go to Top